Balsalazide

Drug Profile

Balsalazide

Alternative Names: Ao Rui Xin; Balacol; Balsalazide disodium; Balsalazine; Balzide; Basazyde; Benoquin; BX 661A; Colazal; Colazid; Colazide; Giazo; Premid

Latest Information Update: 25 Mar 2017

Price : $50

At a glance

  • Originator Biorex Laboratories
  • Developer IVAX Corporation; Pharmatel; Salix Pharmaceuticals; Shire
  • Class Anti-inflammatories; Irritable bowel syndrome therapies; Salicylates; Small molecules
  • Mechanism of Action Arachidonic acid inhibitors; Cyclooxygenase inhibitors; Prostaglandin synthase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Ulcerative colitis
  • Discontinued Cancer; Radioprotection

Most Recent Events

  • 07 Apr 2015 Launched for Ulcerative colitis in China, Philippines, Taiwan, Singapore, Thailand, Myanmar, Malaysia, Hong Kong, Indonesia, United Arab Emirates and India (PO) before April 2015
  • 01 Apr 2015 Salix Pharmaceuticals has been acquired by Valeant Pharmaceuticals International
  • 03 Feb 2012 Balsalazide 1100 mg tablet Registered for Ulcerative colitis in USA (PO)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top